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Abstract 
Background: Photoimmunotherapy involves targeted delivery of photosensitizers via an antibody conjugate (i.e., 
photoimmunoconjugate, PIC) followed by light activation for selective tumor killing. The trade‑off between PIC 
selectivity and PIC uptake is a major drawback limiting the efficacy of photoimmunotherapy. Despite ample evidence 
showing that photoimmunotherapy is most effective when combined with chemotherapy, the design of nanocarriers 
to co‑deliver PICs and chemotherapy drugs remains an unmet need. To overcome these challenges, we developed 
a novel photoimmunoconjugate‑nanoliposome (PIC‑Nal) comprising of three clinically used agents: anti‑epidermal 
growth factor receptor (anti‑EGFR) monoclonal antibody cetuximab (Cet), benzoporphyrin derivative (BPD) photosen‑
sitizer, and irinotecan (IRI) chemotherapy.
Results: The BPD photosensitizers were first tethered to Cet at a molar ratio of 6:1 using carbodiimide chemistry to 
form PICs. Conjugation of PICs onto nanoliposome irinotecan (Nal–IRI) was facilitated by copper‑free click chemistry, 
which resulted in monodispersed PIC–Nal–IRI with an average size of 158.8 ± 15.6 nm. PIC–Nal–IRI is highly selective 
against EGFR‑overexpressing epithelial ovarian cancer cells with 2‑ to 6‑fold less accumulation in low EGFR expressing 
cells. Successful coupling of PIC onto Nal–IRI enhanced PIC uptake and photoimmunotherapy efficacy by up to 30% 
in OVCAR‑5 cells. Furthermore, PIC–Nal–IRI synergistically reduced cancer viability via a unique three‑way mechanism 
(i.e., EGFR downregulation, mitochondrial depolarization, and DNA damage).
Conclusion: It is increasingly evident that the most effective therapies for cancer will involve combination treat‑
ments that target multiple non‑overlapping pathways while minimizing side effects. Nanotechnology combined with 
photochemistry provides a unique opportunity to simultaneously deliver and activate multiple drugs that target all 
major regions of a cancer cell—plasma membrane, cytoplasm, and nucleus. PIC–Nal–IRI offers a promising strategy 
to overcome the selectivity‑uptake trade‑off, improve photoimmunotherapy efficacy, and enable multi‑tier cancer 
targeting. Controllable drug compartmentalization, easy surface modification, and high clinical relevance collectively 
make PIC–Nal–IRI extremely valuable and merits further investigations in living animals.
Keywords: Photoimmunoconjugate, Irinotecan liposome injection, Benzoporphyrin derivative, Epidermal growth 
factor receptor, Multi‑drug delivery
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Background
Photoimmunotherapy (PIT) employs antibody-pho-
tosensitizer conjugates (i.e., photoimmunoconjugates, 
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to induce reactive oxygen species (ROS)-mediated (e.g., 
1O2,  O2•–, •OH) tumor destruction while sparing normal 
tissues [1–4]. The fluorescence signal generated from the 
excited photosensitizers can be used for optical imag-
ing and fluorescence-guided surgery (FGS) of tumors 
[5]. Epidermal growth factor receptor (EGFR) has long 
represented an oncologic target of immense interest, 
and it is overexpressed in several malignancies, includ-
ing head and neck cancer, ovarian cancer, and glioblas-
toma [6]. Since the introduction of PIT in the ‘80s [4], 
several EGFR-targeted PICs (e.g., cetuximab-IRDeye700 
and panitumumab-IRDye800) are now in clinical tri-
als for PIT or FGS (NCT02422979, NCT03384238). We 
previously developed a PIC system that comprises of the 
U.S. Food and Drug Administration (FDA)-approved 
anti-EGFR monoclonal antibody cetuximab (Cet) and 
a clinically used benzoporphyrin derivative (BPD) pho-
tosensitizer to target cancer cells [7–11]. The highly 
self-quenched BPD molecules conjugated to Cet can be 
de-quenched (activated) by cancer cells via lysosomal 
proteolysis of the antibody [7, 10, 11]. It is also well-
established that light activation of BPD induces photo-
chemical disruption of the mitochondrial membrane [9], 
which triggers the release of cytochrome c, a potent ini-
tiator of apoptotic cell death [12–14]. This shifts the bal-
ance in the target cells from an anti-apoptotic state to a 
more pro-apoptotic state, mediating eventual cell death.
While PIT leverages PIC to minimize damage to healthy 
tissues, it requires an optimal intracellular PIC concentra-
tion threshold for effective tumor destruction [9, 11]. One 
of the strategies to overcome the insufficient PIC uptake is 
to combine nanotechnology with PIC. With a high surface 
area-to-volume ratio, nanoparticles can be decorated with 
large amounts of antibodies for tumor targeting [15]. We 
recently demonstrated that immobilization of PIC onto 
poly(lactic-co-glycolic acid) (PLGA) nanoparticles could 
facilitate the indirect endocytosis of high payloads of PIC 
under limited antibody-receptor binding events, overcom-
ing the persistent challenge of insufficient PIC uptake by 
cancer cells [10]. However, it remains unclear if this ‘car-
rier effect’ phenomenon with PIC and PLGA nanoparticles 
could be extended to other types of nanoformulations at 
large. In this study, we seek to verify the generalizability of 
this phenomenon using a novel photoimmunoconjugate-
nanoliposome (PIC–Nal) formulation. Furthermore, the 
PIC–Nal is rationally designed to co-deliver irinotecan 
chemotherapy for enhanced PIT outcomes.
Nanoliposomal irinotecan injection (Onivyde®, Nal–
IRI) is a valuable chemotherapy given in combination 
with fluorouracil and leucovorin to patients with gem-
citabine-refractory metastatic pancreatic cancer, and it is 
now being tested in patients with gastric adenocarcinoma 
(NCT03739801), gynecological cancer (NCT01770353), 
lung cancer (NCT03088813), and glioblastoma 
(NCT03119064) [16–19]. Irinotecan acts by inhibiting 
topoisomerase I (Top1) and trapping Top1-DNA cleav-
age complexes (Top1cc) to induce double-stranded DNA 
breaks in the nucleus and promote direct cell death [20]. 
We have shown that light activation of BPD (i.e., pho-
todynamic therapy, PDT) synergizes with irinotecan to 
improve survival outcomes in pancreatic cancer mouse 
models [21–23]. Similarly, others also demonstrated 
that light activation of irinotecan-loaded porphysomes 
reduces pancreatic tumor burden [24]. However, all 
these studies utilized ‘non-targeted’ nanoliposomes car-
rying ‘unquenched’ photosensitizers that are at a higher 
risk of normal tissue phototoxicity. Here, we leverage our 
‘tumor-activatable’ PIC system (i.e., Cet-BPD) [7, 9] to 
improve the selectivity and efficacy of irinotecan.
For many combinations to achieve optimal efficacy, 
spatiotemporal control of drug exposure to coordinate 
targeted inhibition of interconnected cancer survival 
and growth pathways is of paramount importance [25, 
26]. In addition to targeting multiple survival pathways 
or blocking cell death escape mechanisms, drugs that are 
the best candidates for combination are those that target 
all major regions of a cell (i.e., plasma membrane, cyto-
plasm, and nucleus) and also have non-overlapping tox-
icities [27, 28]. Hybrid nanocarriers, such as those based 
on PICs and nanoliposomes, are particularly promising 
approaches for combination therapies because they can 
be designed to compartmentalize multiple agents at a 
fixed ratio, target deliver therapeutics to cancer cells at a 
high payload, and generate cytotoxic ROS upon light acti-
vation [29]. Here, we interface PIC and nanoliposomal 
irinotecan for targeted photoimmuno-chemotherapy. We 
anticipate the mechanism-based nanotechnology com-
prising Cet, BPD, and irinotecan will be more effective in 
reducing cancer viability by targeting different subcellu-
lar components as well as molecular pathways, compared 
to monotherapies. The following studies demonstrate 
how photoimmuno-chemotherapy addresses one of the 
major challenges facing PIT (i.e., PIC uptake) and pro-
vides compelling evidence that cooperative targeting 
EGFR, mitochondrial, and DNA can markedly improve 
treatment efficacy against cancer.
Results
Synthesis and characterization of PIC–Nal and PIC–Nal–IRI
Unilaminar nanoliposome (Nal) and nanoliposomal 
irinotecan (Nal–IRI), prepared via freeze–thaw cycle 
method, are 126.5 ± 3.5 nm and 151.0 ± 11.7 nm in diam-
eter, respectively with a narrow size distribution (Poly-
dispersity index, PdI < 0.1) (Fig. 1a; Table 1). To minimize 
the non-specific electrostatic interactions with the cell 
membrane and to maximize the contribution of specific 
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interactions to binding and internalization [30, 31], the 
surface charge of nanoformulations was engineered 
to be neutral-to-slightly negative (between − 13.6  mV 
and − 19.6  mV; Table  1) by incorporating 6.9  mol% of 
dioleoylglycerophosphoglycerol (DOPG) into the lipid 
composition. To prepare PIC, BPD molecules were con-
jugated to Cet using carbodiimide chemistry (Fig.  1b). 
Overnight reaction of BPD-N-hydroxysuccinimide ester 
and Cet at 3:1, 6:1, and 9:1 molar ratios resulted in the 
formation of PICs with ~ 2, 4, and 6 BPD molecules 
per Cet, respectively. This corresponds to ~ 67% con-
jugation efficiency (Additional file  1: Table  S1). Click 
chemistry conjugation of azide-functionalized PICs to 
DBCO-containing Nal or DBCO-containing Nal–IRI 
resulted in the formation of PIC–Nal and PIC–Nal–IRI 
with diameters of 142.5 ± 5.9  nm and 158.8 ± 15.6  nm, 
respectively (PdI < 0.1) (Table  1). The conjugation effi-
ciency of PIC to Nal was ~ 66% (Table  1), which corre-
sponds to ~ 40 PICs per Nal. Increasing the BPD-to-Cet 
ratio of PIC did not significantly alter the size, surface 
charge, or conjugation efficiency of the PIC–Nal (Addi-
tional file  1: Table  S2). Irinotecan was passively encap-
sulated in the aqueous core of Nal and PIC–Nal at 
encapsulation efficiencies of 38.8 ± 4.4% and 23.7 ± 2.2%, 
respectively. The conjugation efficiency of PIC to Nal–
IRI was 48.0 ± 2.7%, which corresponded to ~ 33 PICs 
Fig. 1 Schematic diagram of the steps for photoimmunoconjugate nanoliposomal irinotecan (PIC–Nal–IRI) synthesis. a Synthesis and 
cryogenic electron microscopy image of monodispersed nanoliposomal irinotecan (Nal–IRI) with an average size of ~ 150 nm (PdI < 0.1, n > 3). b 
Benzoporphyrin derivative (BPD) was covalently conjugated onto cetuximab (Cet) via carbodiimide chemistry to form photoimmunoconjugate 
(PIC). Copper‑free click chemistry was employed to tether PICs onto Nal–IRI to form PIC–Nal–IRI with an average size of 158.8 ± 15.6 nm (PdI < 0.1, 
n > 3)
Table 1 Physical characterization of the nanoformulations
Nal nanoliposome, PIC–Nal photoimmunoconjugate-nanoliposome, Nal–IRI nanoliposomal irinotecan, PIC–Nal–IRI photoimmunoconjugate-nanoliposomal irinotecan
a Encapsulation efficiency (%): The molar ratio of irinotecan within the liposome after purification to that added initially. bConjugation efficiency (%): The molar ratio 
of PIC conjugated onto the liposomal construct to that added initially
Sample Size (d. nm) Polydispersity 
index (PdI)







Nal 126.5 ± 3.5 0.08 ± 0.01  − 19.6 ± 0.7 N/A N/A N/A
PIC–Nal 142.5 ± 5.9 0.06 ± 0.01  − 13.6 ± 0.6 N/A 66.5 ± 2.3 39.9 ± 1.4
Nal–IRI 151.0 ± 11.7 0.08 ± 0.01  − 16.6 ± 0.4 38.8 ± 4.4 N/A N/A
PIC–Nal–IRI 158.8 ± 15.6 0.09 ± 0.03  − 14.8 ± 0.3 23.7 ± 2.2 48.0 ± 2.7 32.6 ± 2.6
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per Nal–IRI. Drug release profiles of Nal–IRI and PIC–
Nal–IRI were examined in human serum-containing 
medium at 37  °C (Fig.  2a). At 1  h post-incubation, we 
observed ~ 20% and ~ 42% release of irinotecan from the 
Nal–IRI and PIC–Nal–IRI, respectively. The relatively 
fast irinotecan release from PIC–Nal–IRI (t1/2 = 2  h) 
compared to Nal–IRI (t1/2 = 2.3  h) is likely due to the 
presence of PIC, suggesting that irinotecan will be readily 
available to the cancers cells when PIT occurs. Stability 
studies showed that 4-month dark storage at 4 °C did not 
significantly alter the overall size and monodispersity of 
Nal–IRI and PIC–Nal–IRI (Fig. 2b, c).
Photoactivity of PIC–Nal and PIC–Nal–IRI
Hydrophobic BPD has a poor water solubility (< 0.05 mg/
mL) and readily aggregates in biologically relevant media 
[32]. Conjugation of BPD to pegylated Cet enhances BPD 
solubility and allows precise control of BPD quench-
ing and de-quenching [9]. We have previously shown 
that self-quenched BPD molecules on Cet can be de-
quenched by cancer cells upon lysosomal proteolysis of 
the Cet, and thereby increasing the tumor specificity [9–
11]. Prior to photoactivity evaluation, we confirmed that 
PIC, PIC–Nal and PIC–Nal–IRI do not alter the Q band 
of BPD (690 nm; Fig. 3a, b).
In Fig.  3c, due to the aggregation of BPD molecules 
in PBS, the absorbance values at 690  nm for free BPD 
and PIC in PBS were significantly reduced by ~ 64% 
and ~ 48%, respectively, compared to those fully dis-
solved in dimethyl sulfoxide. On the other hand, PIC–Nal 
showed a less pronounced (~ 28%) loss of absorbance 
value at 690 nm in PBS compared to that fully dissolved 
in DMSO (Fig.  3c). This is presumable due to the pres-
ence of PEG (~ 5  mol%) on the Nal that helps mitigate 
PIC aggregation in PBS. Loading of irinotecan into the 
aqueous core of PIC–Nal did not alter BPD’s absorbance 
value at 690 nm (Fig. 3c). Both free BPD and PIC showed 
poor photoactivity due to the static fluorescence quench-
ing of BPD molecules as reported by us previously 
(Fig.  3d) [7, 9–11]. In contrast, PIC–Nal and PIC–Nal–
IRI exhibit up to 45% of photoactivity. This suggests that 
BPD molecules on PIC–Nal and PIC–Nal–IRI are more 
readily activated by light for PIT in biologically relevant 
media compared to PIC (Fig. 3d). We next examined the 
singlet oxygen (1O2) yield of free BPD, PIC, and PIC–Nal 
using singlet oxygen sensor green (SOSG) probes. Upon 
light activation, the SOSG fluorescence intensity gener-
ated by PIC–Nal was significantly higher than that of free 
BPD, PIC and Nal (Fig. 3e), indicating that PIC–Nal has a 
higher 1O2 yield than BPD, PIC, or Nal. We also showed 
that simply mixing PIC with Nal (i.e., ‘PIC + Nal’) does 
not improve the 1O2 yield of PIC, confirming that the 
enhanced 1O2 yield of PIC-Nal relies on the successful 
click chemistry coupling of PICs onto Nal.
Selectivity and uptake of PIC–Nal in cancer cells
We next investigated if PIC–Nal can selectively deliver 
Nal to EGFR-overexpressing cells by comparing the selec-
tive uptake of PIC–Nal and Nal in EGFR(+) OVCAR-5 
cells and EGFR( −) J774 macrophages at a fixed Nal con-
centration (based on rhodamine incorporation). After 
30  min of incubation at 37  °C, PIC–Nal uptake is 2- to 
6-fold higher than Nal uptake in EGFR(+) OVCAR-5 
cells (Fig.  4a). In contrast, PIC–Nal uptake was compa-
rable to Nal uptake in EGFR(–) J774 macrophages. These 
results suggest PIC–Nal selectively binds to EGFR( +) 
cells over EGFR(–) cells. We also observed a reduc-
tion in the EGFR-targeting capability of PIC–Nal with 
increasing BPD:Cet ratio from 2:1 to 6:1 (Fig.  4a), indi-
cating excessive loading of BPD on Cet can compromise 
the selectivity of the antibody. We next tested if cancer-
selective PIC–Nal can improve the overall uptake of PIC 
Fig. 2 Drug release and the stability of Nal–IRI and PIC–Nal–IRI. a Both Nal–IRI and PIC–Nal–IRI exhibited similar irinotecan release profiles 
in serum‑containing medium at 37 °C. b, c The long‑term stability of Nal–IRI and PIC–Nal–IRI (4 °C, PBS) in dark was assessed by longitudinal 
monitoring of changes in b hydrodynamic size and c polydispersity index
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in EGFR-overexpressing OVCAR-5 cells at 24  h post-
incubation. Compared to PIC alone, we observed that 
PIC–Nal enhances (P < 0.05) the intracellular BPD uptake 
by 95%, 56%, and 32% at BPD:Cet molar ratios of 2:1, 4:1 
and, 6:1, respectively (Fig.  4b). In contrast, this ‘carrier 
effect’ was not present in the low EGFR expressing U87 
cells (Additional file 1: Figures S2, S3).
Leveraging the diagnostic capabilities of BPD fluores-
cence, we visualized the intracellular uptake of free BPD, 
PIC, and PIC–Nal in OVCAR-5 cells at 24 h post-incuba-
tion (Fig. 4c). Hydrophobic BPD can easily partition into 
the plasma membrane of both cancerous and non-malig-
nant cells. Thus, it is not surprising that free BPD shows 
the highest uptake in OVCAR-5 cells compared to PIC 
and PIC–Nal. However, free BPD lacks selectivity against 
EGFR-overexpressing cancer cells, and thus will more 
likely induce off-target phototoxicity in  vivo. Fluores-
cence microscopy images show that PIC–Nal modestly 
enhanced intracellular BPD accumulation compared to 
PIC alone (Fig. 4c), which agrees with our findings using 
the extraction method (Fig.  4b). Incubation with PIC–
Nal led to a significant intracellular accumulation of Nal, 
indicated by the intense rhodamine fluorescence signals 
(Fig. 4c). This suggests the potential of delivering another 
therapeutic agent at a high payload using PIC–Nal. These 
studies verified that PIC–Nal not only enables EGFR-
targeted delivery of Nal, but also serves as a platform to 
enhance PIC uptake in EGFR(+) cancer cells (Fig. 4d).
Fig. 3 Photophysical and photochemical characterizations of PIC, PIC–Nal, and PIC–Nal–IRI. a Absorbance spectra of BPD, PIC, and PIC–Nal in DMSO 
showing overlapping main peaks centered at 435 nm (Soret band) and 690 nm (Q band; wavelength for light activation). b Absorbance spectra of 
irinotecan (IRI), Nal–IRI, and PIC–Nal–IRI in DMSO. c A comparison of the 690 nm absorbance value of BPD, PIC, PIC–Nal, and PIC–Nal–IRI in DMSO 
and PBS at a fixed BPD concentration. d Photoactivity of BPD, PIC, PIC–Nal, and PIC–Nal–IRI. Photoactivity is defined in the Methods section. e 
SOSG reports 1O2 production from free BPD, PIC, PIC–Nal, Nal, and ‘PIC + Nal’ in PBS with and without light activation at 690 nm. (n > 3; **P < 0.01, 
***P < 0.001; n.s.: not significant; one‑way ANOVA, Tukey’s posthoc test)
(See figure on next page.)
Fig. 4 Selective binding, uptake, and imaging of PIC–Nal in cancer cells. a The selectivity of PIC–Nal was assessed in EGFR(−) J774 and EGFR(+) 
OVCAR‑5 cells after 30 min of incubation. Nal alone was used as a control. The BPD:Cet ratio of PIC was varied (2:1, 4:1, 6:1). b The uptake of PIC–
Nal and PIC in OVCAR‑5 cells was assessed at 24 h after incubation, based on intracellular BPD fluorescence signal. c Representative fluorescence 
images of OVCAR‑5 incubated with BPD, PIC, or PIC–Nal for 24 h. The BPD:Cet ratio of PIC was fixed at 6:1. Fluorescence signal of the nuclei (DAPI), 
BPD, and nanoliposome (rhodamine) shown in blue, green, and red, respectively (scale bar = 35 µm). d Depiction of the ‘carrier effect’ of PIC–Nal in 
EGFR(+) cancer cells. (n > 3; *P < 0.05, ***P < 0.001; n.s.: not significant; one‑way ANOVA, Tukey’s posthoc test)
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PIC–Nal delivers irinotecan for synergistic 
photoimmuno‑chemotherapy in vitro
We investigated if PIC–Nal is more phototoxic than PIC 
using OVCAR-5 cells. U87 cells expressing lower EGFR 
levels served as a control (Additional file  1: Figure S1). 
At 24 h after light activation (20 J/cm2), PIC–Nal signifi-
cantly reduced OVCAR-5 viability by ~ 60%, compared 
to ~ 35% viability reduction achieved by using PIC at a 
fixed BPD:Cet ratio of 6:1 (Fig. 5a, b). Similar results were 
observed using PIC and PIC–Nal with lower BPD:Cet 
ratios of 2:1 and 4:1 (Additional file  1: Figure S2). All 
samples, including PIC–Nal alone, PIC alone, and Nal 
alone, have negligible dark toxicity (Fig.  5b). In U87 
cells, we observed no statistically significant difference in 
phototoxicity between PIC–Nal and PIC (Fig.  5c, Addi-
tional file 1: Figure S3), suggesting that the ‘carrier effect’ 
of PIC–Nal is, in part, dependent on the level of EGFR 
expression in cancer cells.
PIC–Nal not only improved PIT efficacy against 
EGFR-overexpressing cancer cells, but provided us an 
opportunity to co-deliver irinotecan chemotherapy to 
further enhance treatment outcomes. We next evalu-
ated the therapeutic efficacy of PIC–Nal–IRI at vari-
ous light fluences (0–0.6  J/cm2) in OVCAR-5 and U87 
cells (Fig.  6a). Control groups include Nal–IRI alone, 
PIC alone, PIC–Nal alone, and simply mixing PIC with 
Nal–IRI (‘PIC + Nal–IRI’) at fixed drug concentrations 
(i.e., irinotecan: 7 μM and BPD: 1 μM). The molar ratio of 
BPD-to-Cet was fixed at 6:1. In OVCAR-5 (Fig. 6b) and 
U87 cells (Fig.  6c), 72  h of Nal–IRI-treatment reduced 
cell viability by ~ 20–25%. Light activation of Nal–IRI 
alone did not alter the cell viability (P > 0.05). Both PIC 
and PIC–Nal alone showed minimal dark toxicity (< 15% 
viability reduction) (Fig.  6b, c). A light dose dependent 
reduction in cell viability was observed in both PIC- and 
PIC–Nal-treated cells. PIC–Nal was consistently found 
to be ~ 10–15% more phototoxic compared to PIC alone 
in OVCAR-5, but not in U87 cells. The  IC50 of PIC–Nal 
upon light activation was approximately 0.6  μM × J/
cm2 and 0.35  μM × J/cm2 for OVCAR-5 and U87 cells, 
respectively (Fig.  6b, c). In OVCAR-5 cells, while both 
PIC–Nal–IRI and ‘PIC +  Nal–IRI’ showed similar pho-
totoxicity at 0.2  J/cm2 or below, we observed that PIC–
Nal–IRI out-performs ‘PIC + Nal–IRI’ at or above 0.5  J/
cm2 (Fig.  6b). At 0.6  μM × J/cm2, we showed that PIC–
Nal–IRI is ~ 20% more cytotoxic than ‘PIC + Nal–IRI’ 
in OVCAR-5 cells (P < 0.001) (Fig. 6d). In contrary, both 
PIC–Nal–IRI and ‘PIC + Nal–IRI’ showed similar photo-
toxicity in U87 cells (Fig. 6e).
We further explored the combination interactions 
between the no-treatment (NT), PIC alone, Nal–IRI 
alone, and PIC–Nal–IRI groups (Fig.  6f, g). Using 
Fig. 5 Phototoxicity of PIC–Nal and PIC in OVCAR‑5 and U87 cells. a Cells were incubated with PIC or PIC–Nal at a fixed BPD concentration 
(0.25 µM) for 24 h prior to light activation (690 nm, 20 J/cm2, 150 mW/cm2). Cell viability was determined by MTT assay at 24 h post‑light activation. 
PIC–Nal is more phototoxic than PIC in b high EGFR expressing OVCAR‑5 but not in c low EGFR expressing U87. (n > 3; *P < 0.05, ***P < 0.001; n.s.: not 
significant; one‑way ANOVA, Tukey’s posthoc test)
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CompuSyn software and robust regression fits of the 
dose–response curve trend lines  (R2 = 0.914–0.999) [33, 
34], the combination index (CI) values were calculated 
to determine if combination of PIT and Nal–IRI using 
PIC–Nal–IRI is synergistic (CI < 1), additive (CI = 1), or 
antagonistic (CI > 1). In OVCAR-5 cells, combination of 
PIT and Nal–IRI using PIC–Nal–IRI is additive at 0.3 J/
cm2 (CI 0.97 ± 0.09), and synergistic at 0.5 and 0.6 J/cm2 
Fig. 6 Combination of PIT and Nal–IRI in OVCAR‑5 and U87 cells. a Cells were incubated with PIC–Nal–IRI or controls at a fixed BPD (1 µM) and 
irinotecan (7 µM) concentration for 48 h prior to light activation (690 nm, 10 mW/cm2, 0–0.6 J/cm2). b OVCAR‑5 viability and c U87 viability were 
determined by MTT assay at 24 h post‑light activation. The  IC50 values of PIC–Nal are ~ 0.6 μM × J/cm2 and ~ 0.35 μM × J/cm2 for d OVCAR‑5 
and e U87 cells, respectively. d, e The reduction of cell viability was compared among the treatment groups. f, g Combination index (CI) was 
determined using CompuSyn software. The CI value quantitatively defines synergism (CI < 1), additive effect (CI = 1) and antagonism (CI > 1) effect 
of light‑activated PIC–Nal–IRI in OVCAR‑5 and U87 cells. (n > 3; *P < 0.05, ***P < 0.001; n.s.: not significant; one‑way ANOVA, Tukey’s post hoc test)
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(CI 0.76 ± 0.12 and 0.54 ± 0.19, respectively). Therapeu-
tic synergy was observed in a light dose dependent man-
ner in OVCAR-5 cells (Fig. 6f ), but not in U87 cells (CI 
1.2 ± 0.1) (Fig. 6g).
Multi‑tier cellular targeting using PIC–Nal–IRI
The uniqueness of PIC–Nal–IRI lies, in part, in the 
multi-tier cellular targeting abilities. Three mechanisti-
cally distinct therapeutics (i.e., Cet, BPD, and irinotecan) 
were incorporated in PIC–Nal–IRI to target the EGFR, 
mitochondria, and DNA, respectively (Fig. 7a). Downreg-
ulation of total EGFR expression was observed after 24 h 
of PIC–Nal–IRI incubation and persisted throughout the 
treatment duration up to 72 h (Fig. 7b, c). Nal–IRI alone 
did not alter the EGFR expression (Additional file 1: Fig-
ure S4a). Irinotecan induced DNA damage was evaluated 
by monitoring the expression level of γ-H2AX [35]. PIC–
Nal–IRI significantly upregulated γ-H2AX expression at 
72  h post-incubation (Fig.  7d), indicating DNA double-
strand breaks. γ-H2AX expression was found to be simi-
lar across all different groups (i.e., NT, Nal–IRI, PIC, and 
PIC–Nal–IRI) at 48 h post-incubation (Additional file 1: 
Figure S4b). We have recently shown that proteolyzed 
PIC co-localizes to mitochondria after 24 h and induces 
mitochondrial membrane potential (ΔΨm) depolariza-
tion upon light activation in glioma cells [9]. Here, we 
measured ΔΨm depolarization in OVCAR-5 cells at 24 h 
after light activation of PIC-Nal-IRI or controls (Fig. 7e). 
Light activation of PIC, PIC–Nal, or PIC–Nal–IRI all 
induced a high level of ΔΨm depolarization in OVCAR-5 
cells (Fig.  7e). No ΔΨm depolarization was observed 
using Nal–IRI alone (Fig. 7e).
Discussion
PIC is a promising and exciting tool in the armamen-
tarium for cancer treatment, surgery, and imaging 
[1–3, 11]. However, the selectivity-uptake trade-off 
remains the major drawback limiting the application 
of PIC technology. Previous elegant works have shown 
that PIC (Cet-BPD) is highly selective against cancer 
cells overexpressing EGFR with 20-fold less accumula-
tion in low EGFR cells [7, 36, 37]. The Cet-BPD also has 
a high tumor-to-normal tissue ratio (T/N) of 9.2, which 
mitigates bowel phototoxicity [11]. Despite high tumor 
selectivity, we recently discovered that the intracellular 
uptake of Cet-BPD is six fold less than that of free BPD 
in EGFR-overexpressing cancer cells, significantly reduc-
ing the anti-cancer phototoxicity by 20-fold [9]. To break 
through this selectivity-uptake trade-off, we introduced 
an engineering approach that leverages click chemistry 
to covalently tether large amounts of PICs (Cet-BPD) 
onto the surface of a Nal. We demonstrated that PIC–
Nal is not only highly selective to EGFR-overexpressing 
OVCAR-5 cells with 2- to 5-fold less accumulation 
in macrophage cells, but also enhances PIC uptake in 
OVCAR-5 by ~ 20–30%, overcoming the selectivity-
uptake trade-off and improving the overall PIT efficacy.
Similar results were observed by us previously using 
PIC-PLGA nanoparticles (PIC-NP) in OVCAR-5 and 
U87 cells, indicating the generalizability of this approach 
[10]. However, unlike PIC-NP, in this study, PIC–Nal did 
not enhance the PIC accumulation in low EGFR-express-
ing U87 cells. We speculate this discrepancy is attributed 
to the larger size (steric hindrance) and a lower PIC sur-
face density of PIC–Nal (~ 150  nm, ~ 32 PICs per Nal), 
compared to the smaller size PIC-NP (~ 100 nm) with a 
higher PIC surface density (~ 75 PICs per NP). In fact, 
Gonzalez-Rodriguez et  al. [38] have reported that cyto-
plasmic rigidity could limit the internalization of larger 
particles with radii above the optimal radius (typically 
around 50 nm) via receptor-mediated endocytosis. Vácha 
et  al. [39] have also shown that increasing the antibody 
coverage on the surface of nanoparticles or the antibody-
receptor binding affinity can improve receptor-mediated 
endocytosis. Based on these studies and our results, we 
believe that conjugation of PICs onto a nanoplatform 
to boost the cancer-selective PIC uptake is also contin-
gent upon several important parameters, including par-
ticle size, PIC density, and PIC binding affinity of the 
nanoplatforms, which warrants further investigation and 
optimization.
PDT has been shown to reverse chemoresistance, syn-
ergize with chemotherapeutics and biologics, and over-
come compensatory survival pathways used by cancer 
cells to evade treatment [40–44]. We have also shown 
that PDT synergizes with irinotecan to reduce metastatic 
burden and improve survival outcomes in pancreatic 
tumor mouse models via a two-way mechanism, in which 
(i) PDT photodamages ABCG2 drug efflux transporters 
to prevent irinotecan efflux, and (ii) irinotecan alleviates 
PDT-induced tumor hypoxia [21–23]. However, these 
studies utilized ‘non-targeted’ nanoliposomal irinotecan 
and ‘unquenched’ photosensitizers that are at a higher 
risk of normal tissue toxicity. A major advance of this 
study lies in our ability to reproducibly incorporate iri-
notecan into PIC–Nal for synergistic, targeted photoim-
muno-chemotherpy. It has already been shown that the 
therapeutic synergy of combination treatments depends, 
in part, on the delivery of multiple drugs at a fixed molar 
ratio to cancer cells [45]. Here, we showed that PIC–Nal–
IRI, co-delivering a fixed irinotecan-to-BPD molar ratio 
at 7:1, could be activated by light at low light fluences 
(0.5–0.6  J/cm2) for synergistic reduction of cancer cell 
viability (CI < 0.76). Further optimization of the irinote-
can-to-PIC ratio in PIC–Nal–IRI is likely needed to max-
imize treatment outcomes in  vivo. Another important 
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Fig. 7 Multi‑tier cancer targeting. a Schematic of multi‑tier cancer targeting mechanism: (1) EGFR binding, endocytosis, and proteolysis of PIC–
Nal–IRI, (2) PIT‑mediated depolarization of mitochondrial membrane potential, and (3) irinotecan‑induced DNA damage, leading to synergistic 
cell killing. b Immunoblotting of EGFR and γ‑H2AX expression in OVCAR‑5 cells at different time points after treatment. Quantitative analyses 
of normalized c EGFR and d γ‑H2AX expressions in OVCAR‑5 cells. e Mitochondrial membrane depolarization was assessed at 24 h post‑light 
irradiation (0.35 J/cm2, 10 mW/cm2). (n = 3; *P < 0.05; **P < 0.01; ***P < 0.001; n.s.: not significant; one‑way ANOVA, Tukey’s post hoc test)
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finding is that PIC–Nal–IRI exhibits significantly higher 
OVCAR-5 cell phototoxicity by 20% (P < 0.001), com-
pared to using the unconjugated mixtures of ‘PIC + Nal–
IRI,’ which is an often-overlooked control during the 
development of multi-drug nanomedicine. In low EGFR 
expressing U87 cell, PIC–Nal–IRI and unconjugated 
mixtures of ‘PIC + Nal–IRI’ had similar phototoxicity at 
0.35 J/cm2 (viability: 34.9 ± 2.0% vs. 36.5 ± 1.9%; P > 0.05), 
but both are superior to Nal–IRI alone or PIC-PIT 
alone (viability: 75.8 ± 2.8% vs. 53.5 ± 4.3%, respectively; 
P < 0.001). These observations suggest that, while combi-
nation of PIT and Nal–IRI is more effective in reducing 
cancer cell viability compared to their monotherapies, 
the co-packaging of PIC and irinotecan in a single nano-
formulation might not be required in low EGFR-express-
ing tumors.
Combination treatments are most effective when tar-
geting not only non-overlapping signaling pathways but 
also different subcellular components [28, 46]. Here, we 
integrated three mechanistically distinct, clinically used 
agents (Cet, BPD, and irinotecan) into a single nano-
platform to target the EGFR, mitochondria, and DNA, 
cooperatively. Similar to previous observations made by 
others and us using PIC or Cet alone [8, 9], we showed 
that PIC–Nal–IRI downregulates EGFR expression as 
soon as 24  h of administration. This also confirms that 
click conjugation of PIC onto Nal does not impair PIC’s 
ability to inhibit EGFR. It is well established that iri-
notecan-induced up-regulation of γ-H2AX, a prominent 
DNA damage marker, typically occurs at 48–72  h after 
incubation. Here, we showed that PIC–Nal–IRI elicits 
DNA breakage at 50 and 72 h after treatment. However, 
we observed that PIC–Nal–IRI transiently downregulates 
γ-H2AX expression in the first 24  h of incubation. This 
is presumably due to the activation of Cet-induced DNA 
repair pathways (e.g., Eme1) as shown by others [47]. 
Lastly, depolarization of the mitochondrial membrane 
was observed at 24 h after light activation of PIC–Nal–
IRI, PIC-Nal, or PIC, but not with Nal–IRI alone, sug-
gesting cytosolic mitochondrial photodamage is achieved 
primarily by PIC, as reported by us [9].
Conclusion
In summary, the selectivity-uptake trade-off of PICs 
and the need of chemotherapy to enhance treatment 
outcomes are two major hurdles limiting the applica-
tion of PIT for cancer management. This study intro-
duces a light-activatable nanoplatform to overcome 
these challenges via a two-pronged approach. First, suc-
cessful conjugation of PICs onto the surface of nanoli-
posomes overcomes the selectivity-uptake trade-off of 
PIC. Second, PIC–Nal–IRI offers a unique opportunity 
to target multiple major components of a cancer cell for 
synergistic therapeutic outcomes. Our in  vitro results 
also point to valuable parameters (e.g., size, PIC den-
sity, and PIC binding affinity) to be optimized prior to 
advancing PIC–Nal–IRI to animal studies.
Methods
Photoimmunoconjugate (PIC) synthesis 
and characterization
Conjugation of BPD to Cet was achieved via carbo-
diimide chemistry [9, 10]. Briefly, Cet (152 kDa; 2 mg/
mL) was pegylated with mPEG-NHS (40k; 16  mg/
mL) overnight. Pegylated Cet was mixed with BPD 
N-hydroxysuccinimidyl ester (BPD-NHS) and azide-
PEG4-N-hydroxysuccinimidyl ester (azide-PEG-NHS) 
at 1:3:2.5, 1:6:2.5, and 1:9:2.5 molar ratios for 20  h. 
The resulting PIC was purified using a 7  kDa MWCO 
Zeba™ spin desalting column that is pre-equilibrated 
with 30% DMSO, and concentrated with a 30 kDa cen-
trifugal filter tube. The purity of PIC was confirmed to 
be over 99% using SDS-PAGE (Additional file 1: Figure 
S5). BPD concentration was determined by UV–Vis 
spectroscopy using established molar extinction coeffi-
cients (Additional file 1: Table S3). Antibody concentra-
tion was determined using BCA assay.
Nanoliposome (Nal) synthesis and characterization
Nanoliposome (Nal) and nanoliposomal irinote-
can (Nal–IRI) were prepared following freeze–thaw 




thanolamine-N-dibenzocyclooctyl polyethylene glycol 
(DSPE-mPEG2000-DBCO), and dioleoylglycerophos-
phoglycerol (DOPG; Avanti) were mixed at a molar 
ratio of 2.8:6:0.4:0.2:0.6. For selectivity and uptake stud-
ies, 0.1  mol% of dipalmitoylglycero-phosphoethanol-
amine-N-(lissamine Rhodamine B sulfonyl) (16:0 Liss 
Rhod PE) was added to the lipid film. The dried lipid 
film was hydrated with deionized water with or with-
out irinotecan (3  mM) prior to freeze–thaw cycling 
(4°C –45  °C). Multi-laminar nanoliposomes were then 
extruded through polycarbonate membrane (What-
man; 0.1  μm) at 45  °C and dialyzed against PBS to 
remove free irinotecan. Zetasizer NanoZS (Malvern) 
determined the size and zeta potential of Nals. The 
concentration of irinotecan was determined using UV–
Vis spectroscopy and the established molar extinction 
coefficients (Additional file 1: Table S3) [21, 22, 48].
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Photoimmunoconjugate‑nanoliposome (PIC‑Nal) 
synthesisand characterization
Photoimmunoconjugate-nanoliposomes (PIC–Nal) and 
photoimmunoconjugate-nanoliposomal irinotecan (PIC–
Nal–IRI) were synthesized via cooper-free click chemis-
try. Briefly, azide-containing PICs were mixed overnight 
with DBCO-containing Nal (or DBCO-containing Nal–
IRI) at a molar ratio of 60:1. Sepharose CL-4B size exclu-
sion chromatography was used to purify PIC–Nal and 
PIC–Nal–IRI. Drug concentrations were determined by 
UV–Vis spectroscopy and established molar extinction 
coefficients (Additional file  1: Table  S3). Singlet oxygen 
sensor green (SOSG, 5  μM) was used to detect singlet 
oxygen (1O2) yield upon light irradiation of PIC–Nal–IRI 
or controls. BPD concentration is fixed at 5 μM. A micro-
plate reader (BioTek) was used to acquire SOSG fluores-
cence signals (Ex/Em: 504/525 nm) before and after light 
irradiation (690 nm, 150 mW/cm2, 20 J/cm2). Photoactiv-
ity is defined as the maximal fluorescence intensity (FI) 
of photosensitizer in PBS divided by the maximal FI of 
photosensitizer in DMSO. The stability of the nanofor-
mulations in PBS was determined by monitoring their 
hydrodynamic size and polydispersity index (PdI) over 
time. Irinotecan release from Nal–IRI and PIC–Nal–IRI 
was studied in 1% human serum at 37 °C under constant 
stirring using a dialysis setup described previously [21, 
22].
Selectivity, Uptake, and Phototoxicity 
of Photoimmunoconjugate‑Nanoliposome (PIC–Nal)
Human ovarian cancer (OVCAR-5), human glioma 
(U87), and murine macrophage (J774) cell lines were pur-
chased from ATCC and cultured in a 37 °C, 5%  CO2 incu-
bator with designated media. Cells were confirmed to 
be free of mycoplasma. For selectivity studies, EGFR(+) 
OVCAR-5 cells or EGFR(−) J774 cells were plated (400 k 
cells/35-mm Petri dish) and allowed to grow overnight. 
Cells were incubated with rhodamine-labeled PIC–Nal 
(or rhodamine-labeled Nal) at a fixed rhodamine con-
centration (0.5  μM) for 30  min (37  °C). After incuba-
tion, cells were washed twice with PBS and dissolved in 
Solvable™. The rhodamine fluorescence signals (Ex/Em: 
545/610  nm) were acquired using a microplate reader 
to determine the selective binding of PIC–Nal. For 
uptake and phototoxicity studies, OVCAR-5 cells (200 k 
cells/35-mm dish) were incubated with PIC–Nal or con-
trols (i.e., PIC alone, no-treatment) at a fixed BPD con-
centration (0.25 μM) for 24 h. For the uptake study, cells 
were washed twice with PBS and dissolved in Solvable™. 
The BPD fluorescence signals (Ex/Em: 435/690 nm) were 
acquired using a microplate reader to quantify the uptake 
of PIC–Nal. In another set of experiment, washed cells 
were fixed with 4% paraformaldehyde, and stained with 
DAPI. Cells were imaged with the LionHeart Imager 
(BioTek) using the 10 x objective to visualize the BPD sig-
nal (Ex/Em: 422/690  nm) and the DAPI signal (Ex/Em: 
358/461 nm). BPD fluorescence intensity was quantified 
using ImageJ [50]. For phototoxicity studies, cells were 
irradiated with a 690 nm laser (20  J/cm2, 150 mW/cm2) 
at 24 h post-incubation of PIC–Nal or controls. Cell via-
bility was determined by MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) assay (Thermo) 
at 24 h post-light activation.
Photoimmuno‑chemotherapy efficacy
To assess photoimmuno-chemotherapy efficacy, 
OVCAR-5 (5 k cells/well) and U87 cells (7 k cells/well), 
cultured in black-wall flat bottom 96-well plates, were 
incubated with PIC–Nal–IRI or controls at fixed drug 
concentrations (i.e., 1 μM of BPD and 7 μM of irinotecan) 
for 48 h prior to light activation (690 nm, 0–0.6 J/cm2, 10 
mW/cm2; Modulight). Cell viability was determined by 
MTT assay at 24  h post-light activation. Mitochondrial 
membrane potential (ΔΨm) was examined via TMRE 
assay (Abcam). For western blot analyses, cell lysates 
(20  µg) were separated on 4–12% precast Bis–Tris pro-
tein gels and transferred onto a PVDF membrane. Subse-
quent to blocking with 5% BSA or milk in TBST solution, 
proteins were further detected using antibodies against 
EGFR (1:1000, Cell Signaling #2239) and γ-H2AX (1:500, 
EMP #05636). Anti β-actin antibodies (1:5000, Cell 
Signaling #3700) were used for the loading control. Vis-
ualization of protein bands was developed via chemilu-
minescence (SuperSignal) with exposure to a Gel Imager 
(ProteinSimple).
Statistical analysis
All experiments were carried out at least in triplicates. 
Specific tests and number of repeats are indicated in the 
figure captions. Results were shown with mean ± stand-
ard error of the mean (SEM). Statistical analyses were 
performed using GraphPad Prism (GraphPad Software).
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Additional file 1: Table S1. Synthesis of photoimmunoconjugates with 
different BPD‑to‑Cetuximab (BPD:Cet) ratios. Table S2. Physical characteri‑
zation of nanoliposome (Nal) and photoimmunoconjugate‑nanoliposome 
(PIC‑Nal) with varying BPD‑to‑Cetuximab (BPD:Cet) ratios of PIC. Table S3. 
Molar extinction coefficients (ε) and equations used to determine the 
irinotecan concentration (CIRI) and BPD concentration (CBPD) of PIC‑Nal‑IRI 
in DMSO using Beer‑Lambert law. Figure S1. Immunoblotting of EGFR in 
human OVCAR‑5 and U87 cells. Whole cell extracts (20 µg) were loaded 
into each lane. β‑actin was used as loading control. OVCAR‑5 cell line has 
a higher EGFR expression compared to U87 cells. Figure S2. Phototoxicity 
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of photoimmunoconjugate‑nanoliposome (PIC‑Nal) at different BPD:Cet 
ratios in human ovarian cancer cells (OVCAR‑5). Cells were incubated with 
PIC or PIC‑Nal at a fixed BPD concentration of 0.25 µM for 24 h before 
light activation at 690 nm (20 J/cm2, 150 mW/cm2, bottom illumination). 
Cell viability was determined by MTT assay at 24 h after photoimmu‑
notherapy (PIT). (n > 3; *P < 0.05; one‑way ANOVA, Tukey’s posthoc test). 
Figure S3. Intracellular BPD fluorescence signals of PIC and PIC‑Nal (at 
different BPD:Cet ratios) were evaluated in human glioma cells (U87) via 
extraction method. Cells were incubated with PIC or PIC‑Nal at a fixed 
BPD concentration of 0.25 µM for 24 h prior to extraction (n > 3; n.s.: not 
significant; one‑way ANOVA, Tukey’s posthoc test). Figure S4. Immunob‑
lotting of EGFR and γ‑H2AX expressions in OVCAR‑5 cells at 24 h and 47 
h after incubation of PIC, Nal‑IRI, and PIC‑Nal‑IRI. Whole cell extracts (20 
µg) were loaded into each lane. β‑actin was used as a loading control. 
(a) Downregulation of EGFR was most pronounced when treated with 
PIC‑Nal‑IRI. (b) The γ‑H2AX expression remained at a similar level across 
different treatment groups. (n = 3; *P < 0.05; **P < 0.01; ***P < 0.001; one‑
way ANOVA, Tukey’s posthoc test). Figure S5. The purity of Cet‑BPD was 
assessed by gel fluorescence imaging analysis following sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS‑PAGE). (a) Coomassie 
blue staining of SDS‑PAGE for visualization of the standards (Ladder), Cet, 
Cet‑BPD (PIC), and BPD. (b) Gel fluorescence imaging (Em: 690 nm) of 
SDS‑PAGE shows < 1% free BPD impurity in PIC; fluorescence intensity was 
quantified using ImageJ.
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